Sequential MitoQ priming followed by combined urolithin A co-administration repairs the accumulated backlog of oxidat...
IF co-administration of urolithin A (50 mg/kg/day via dietary admixture, initiated after a 2-week MitoQ priming phase) and MitoQ (250 µM in drinking water, initiated 2 weeks prior to urolithin A and continued concurrently for 10 weeks total) is delivered to aged male and female C57BL/6 mice (20–24 months old), targeting skeletal muscle and vascular tissue,
THEN the combination will achieve significantly greater reduction in cytoplasmic mtDNA fragment abundance (≥40% versus monotherapy controls, measured by cytoplasmic fraction qPCR for MT-CO1 and MT-ND1), suppression of NLRP3 inflammasome activation markers (IL-1β, cleaved caspase-1 in muscle lysate), increased mitophagy flux (LC3-II/I ratio increase ≥30% over vehicle, with concurrent p62 degradation), reduced steady-state mitochondrial ROS (MitoSOX fluorescence, 8-OHdG levels), improved grip strength (≥15% over vehicle), and improved ex vivo aortic ring endothelial function (ACh-induced relaxation), compared to either compound administered alone, vehicle-treated aged controls, or young (4-month) reference animals,
BECAUSE the causal chain proceeds as follows:
-
In aged tissues, chronically elevated mitochondrial superoxide and hydroxyl radicals oxidize critical cysteine residues within PINK1 (C92, C298) and the RING2 domain of Parkin, rendering both kinase and E3-ligase activities suboptimal, thereby impairing the initiating steps of the PINK1/Parkin mitophagy cascade and allowing a backlog of depolarized, mtDNA-damaged organelles to accumulate — a biochemically documented failure of mitophagy flux in aging. (Mitochondria-to-nucleus retrograde signaling and elevated ROS impair autophagy machinery)[https://doi.org/10.1101/gad.331272.119] [SPECULATIVE: specific cysteine oxidation sites on PINK1 have not been directly demonstrated in vivo in aged muscle; extrapolated from general redox inactivation of kinases by mitochondrial ROS.]
-
During the 2-week MitoQ priming phase, the TPP⁺-conjugated ubiquinone moiety accumulates 100–1,000-fold within the inner mitochondrial membrane driven by membrane potential, where it is continuously recycled by Complex II to its reduced (ubiquinol) form, directly quenching superoxide before it can oxidize PINK1/Parkin, thereby restoring the redox environment necessary for the mitophagy initiation machinery to function — a "priming" of the quality control apparatus rather than clearance per se. (MitoQ accumulates selectively in mitochondria and scavenges ROS at the source)[https://doi.org/10.1161/HYPERTENSIONAHA.117.10787]
-
Following MitoQ-mediated restoration of PINK1/Parkin redox competency, the subsequently introduced urolithin A drives mild, non-apoptotic mitochondrial membrane depolarization, now efficiently recruiting the restored Parkin machinery to the outer membrane of already-accumulated damaged mitochondria — specifically the cohort of aged, superoxide-leaking organelles that previously escaped clearance due to PINK1/Parkin oxidative inhibition. (Uro...
SENS category: LysoSENS
Key references: • doi.org/10.1101/gad.331272.119] • doi.org/10.1161/HYPERTENSIONAHA.117.10787] • doi.org/10.1038/s41591-019-0617-2] • doi.org/10.1101/2024.06.15.24308845] • doi.org/10.1111/joim.12055]